As of November 9, 2026, Sangamo Therapeutics, Inc. is a publicly traded company (ticker SGMOQ); its largest reported holder is Armistice Capital, with 9.38% on Schedule 13G/A of August 14, 2026. The largest insider holding is Sandy Macrae, the chief executive and president, with 1,895,043 shares (0.46% of shares outstanding), per Form 4 of May 27, 2026 (Schedule 13G/A, August 14, 2026).
Is this your company?
About to sign with, pay or invest in Sangamo Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Sangamo Therapeutics, Inc. a real, registered company?
- Sangamo Therapeutics, Inc. files with the SEC under CIK 1001233 (its SEC filings).
- Its shares are listed under the ticker SGMOQ (SEC company record).
- Incorporated in Delaware; business address in Richmond, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court record: no federal case found under SANGAMO THERAPEUTICS, INC. in our court records (as of 2026-11-09).
- Bankruptcy: Sangamo Therapeutics, Inc. filed for Chapter 11, as Sangamo Therapeutics, Inc. reported on Form 8-K on June 23, 2026 (Form 8-K, Item 1.03, filed 2026-06-23).
- Layoffs: 1 exit or restructuring plan reported on Form 8-K, Item 2.05 (latest filed 2026-06-23, about 51 jobs).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Armistice Capital (filed 2026-08-14).
Who are Sangamo Therapeutics, Inc.'s owners and officers?
Sangamo Therapeutics, Inc.: incorporated in Delaware; business address in Richmond, California; industry Biological Products, (No Diagnostic Substances) (Form 8-K, 2026-09-21).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Armistice Capital, LLC | 9.38% |
| Schedule 13G, 2026-05-15 | Armistice Capital, LLC | 9.75% |
| Schedule 13G/A, 2025-11-12 | Wasatch Advisors LP | 2.1% |
Questions about who owns Sangamo Therapeutics, Inc.
Who owns Sangamo Therapeutics, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Sangamo Therapeutics, Inc.: Armistice Capital, LLC (9.38%, Schedule 13G/A, filed 2026-08-14).
When did Armistice Capital, LLC buy into Sangamo Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Armistice Capital, LLC on this page is the Schedule 13G, filed 2026-05-15, reporting 9.75%; its latest, Schedule 13G/A filed 2026-08-14, reports 9.38%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 3 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Sangamo Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Sangamo Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Sangamo Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Sangamo Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 1,895,043 shares (0.46% of shares outstanding) (Form 4, 2026-05-27).
- , the principal financial officer: 660,042 shares (0.16% of shares outstanding) (Form 4, 2026-01-26).
- , the senior vice president and chief legal officer: 647,370 shares (0.16% of shares outstanding) (Form 4, 2026-05-27).
- , the senior vice president-chief development officer: 328,733 shares (0.08% of shares outstanding) (Form 4, 2026-05-27).
- , the principal accounting officer: 235,292 shares (0.06% of shares outstanding) (Form 4, 2026-05-27).
Shares outstanding: 414,288,847 as of 2026-05-11, from the company's latest SEC cover page.
How much has Sangamo Therapeutics, Inc. raised?
Acquisitions reported on Form 8-K, Item 2.01: completed an acquisition (2026-09-21); completed an acquisition (2026-09-08).
What is Sangamo Therapeutics, Inc.'s court and legal record?
Bankruptcy or receivership reported on Form 8-K, Item 1.03: Form 8-K, 2026-09-21, Form 8-K, 2026-09-08, Form 8-K, 2026-08-28 (Chapter 11), Form 8-K, 2026-07-20 (Chapter 11), Form 8-K, 2026-06-23 (Chapter 11).
Red flags found
a bankruptcy or receivership filing by Sangamo Therapeutics, Inc. (Form 8-K, 2026-06-23); 1 exit or restructuring plan on Form 8-K (latest Form 8-K, 2026-06-23).
Keep reading
More on Sangamo Therapeutics, Inc. and the records around it.
Sangamo Therapeutics, Inc. elsewhere on the record
- Layoff notices Jun 2026
- Bankruptcy record
Companies that share a holder
- Wasatch Advisors LP also filed stake reports on 72 other companies: Smith Douglas Homes Corp (Oct 2026), Amtech Systems Inc (Oct 2026), BBB Foods Inc (Oct 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Related pages
LayoffsBankruptcy filings5%+ holders
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/sangamo-therapeutics